PDCD1 and melanoma: Therefore, in this study, the intestinal barrier state biomarkers, fecal zonulin, fecal calprotectin, and fecal SIgA, were quantified in advanced melanoma patients receiving anti-PD-1 therapy, before the start and during treatment, to analyze their association with clinical outcomes.